Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience

American Journal of Transplantation

Volumn 5, Issue 4 I, 2005, Pages 775-780

  Trofe, Jennifer ^a   Buell, Joseph F ^a   Beebe, Thomas M ^a   Hanaway, Michael J ^a   First, M Roy ^a,b   Alloway, Rita R ^a   Gross, Thomas G ^a,c   Succop, P ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Graft survival; Immunosuppression; Multivariate survival analysis; Patient survival; Post transplant lymphoproliferative disorder; Renal transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CAUSE OF DEATH; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISRAEL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME;

GRAFT REJECTION; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; REGISTRIES; SURVIVAL; SURVIVAL ANALYSIS;

EID: 16244386205     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00776.x     Document Type: Article

References (20)

1. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106-112.
2. Trofe J, Buell JF, First MR, Hanaway MJ, Beebe TM, Woodle ES, The role of immunosuppression in lymphoma. Recent Results Cancer Res 2002; 159: 55-66.
3. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984-988.
4. Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res 2002; 159: 81-88.
5. Libertiny G, Watson CJ, Gray DW, Welsh Kl, Morris PJ. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334.
6. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145-155.
7. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19: 772-778.
8. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
9. Choquet S, Mamzer BM, Hermine O, Porcher R, Nguyen QS, Davi F et al. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 67-80.
10. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000; 7: 147-156.
11. Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851-1854.
12. Shiel A. Cancer in Dialysis and Transplant Patients. In: Morris PJ, ed. Kidney Transplantation Principles and Practice. 5th Ed Philadelphia: WB Saunders; 2001. p. 558-570.
13. Preiksaitis JK. Epstein-Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment. Transpl Infect Dis 2001; 3: 56-59.
14. Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barrvirus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97-103.
15. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464.
16. Cosio FG, Nuovo M, Delgado L, Yearsley M, Porcu P, Caligiuri M et al. EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD. Am J Transplant 2004; 4: 116-123.
17. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-727
18. Hanto DW, Frizzera G, Gajl-Peczalska J, Purtilo DT, Klein G, Simmons RL et al. The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc 1981, 13: 756-760.
19. Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004; 22: 262-268.
20. Au HJ, Mulder KE, Fields AL. Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 2003; 3: 165-171.